#ENDO INTERNATIONAL PLC FOUNDER FULL#

'Paul has spent a significant portion of his career leading and operating complex generics businesses and overseeing Par's branded business. Generic and International pharmaceutical assets,' stated Roger H. 'Given the continued evolution of Endo's business and Paul's impressive track record of delivering strong operating results, the Board concluded that Paul is the right leader for Endo at this juncture as we focus on execution and increasing the value of our attractive U.S. Since joining Endo, Campanelli has overseen the Company's U.S. Specifically, during his tenure, Par significantly increased total revenue, acquired JHP Pharmaceuticals and established a presence in the European generics market. While CEO of Par, Campanelli built a strong leadership team and an industry-leading generics business. Campanelli, who will also join Endo's Board of Directors, succeeds Rajiv De Silva, who has stepped down as President, CEO and a member of the Board.Ĭampanelli, 54, joined Endo in 2015 following Endo's acquisition of Par Pharmaceutical, where he had served as Chief Executive Officer since 2012. Campanelli currently serves as President of Endo's Generic and OTC drugs business, Par Pharmaceutical, which accounts for approximately 60 percent of Endo's total revenues through the first half of 2016. Campanelli President and Chief Executive Officer, effective immediately. 23, 2016 /PRNewswire/ - Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Board of Directors has named Paul V.

#ENDO INTERNATIONAL PLC FOUNDER FULL#

This executive's tanure with ENDO INTERNATIONAL is not currenlty determined.Brings Extensive Leadership and Operations Experience in Generics, OTC Drugs and Branded ProductsĬompany Affirms Third Quarter and Full Year 2016 Financial GuidanceĭUBLIN, Sept. and is currently a Member of the Board of Trustees at Kent Place School in Summit NJ. De Silva was a Director of AMAG Pharmaceuticals Inc. He has broad international experience having managed businesses in the United States Europe Canada Latin America Asia South Africa and AustraliaNew Zealand.

De Silva was a Principal at McKinsey Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice.

He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel Switzerland. De Silva also served as President of Novartis Pharmaceuticals Canada. During this time he played a key leadership role at Novartis Vaccines Diagnostics Division. He served as President of Novartis Vaccines USA and Head Vaccines of the Americas at Novartis. De Silva held various leadership positions with Novartis. At Valeant he was responsible for all specialty pharmaceutical operations including sales and marketing research and development manufacturing and business development. from October 2010 to January 2013 and served as its Chief Operating Officer Specialty Pharmaceuticals from January 2009 until January 2013. De Silva joined Endo Health Solutions as Chief Executive Officer and a Director in March 2013 and had served as the President of Valeant Pharmaceuticals International Inc. Rajiv De Silva is President Chief Executive Officer and a Director of Endo International Public Limited Company.

Endo international plc founder